MINDACT
Biomarker Program
Microarray in node-negative and 1 to 3 positive lymph node disease may avoid chemotherapy: a prospective, randomized study comparing the 70-gene signature with the common clinical-pathological criteria in selecting patients for adjuvant chemotherapy in breast cancer with 0 to 3 positive nodes.
Phase 0
Status
Follow up
Tumour subtype:
Biomarker driven
Scenario
Adjuvant
COLLABORATORS
Agendia
Breast International Group
Roche Pharma AG
Novartis
Sanofi
PRINCIPAL INVESTIGATORS
E. Rutgers, MD, PhD (NKI, Amsterdam, Netherlands)
F. Cardoso, MD (Champalimaud Cancer Center, Lisboa, Portugal)
Sites
COMPLEJO HOSPITALARIO HOSPITAL “SAN PEDRO DE ALCANTARA”, HOSPITAL CLÍNICO UNIVERSITARIO DE VALENCIA, HOSPITAL SON ESPASES, HOSPITAL SON LLATZER, HOSPITAL UNIVERSITARI ARNAU DE VILANOVA DE LLEIDA, HOSPITAL UNIVERSITARI VALL D’HEBRON, HOSPITAL UNIVERSITARIO 12 DE OCTUBRE, ICO GIRONA (HOSPITAL DR. JOSEP TRUETA), ICO HOSPITALET (DURAN I REYNALS), INSTITUTO VALENCIANO DE ONCOLOGÍA
